MX2007009985A - Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos. - Google Patents
Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos.Info
- Publication number
- MX2007009985A MX2007009985A MX2007009985A MX2007009985A MX2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxyisoleucine
- diabetes
- type
- isomers
- diastereoisomers
- Prior art date
Links
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 title abstract 2
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 title abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002473 insulinotropic effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invencion se refiere a isomeros configuracionales de 4-hidroxiisoleucina y a lactonas, sales y prodrogas farmaceuticamente aceptables de los mismos, a procesos para su preparacion y a composiciones farmaceuticas que comprenden los mismos. Los isomeros de la invencion exhiben actividad insulinotropica y asi pueden ser utiles para la prevencion y tratamiento de trastornos del metabolismo de carbohidratos o lipidos, incluyendo diabetes mellitus (diabetes tipo 1 y tipo 2), pre-diabetes y Sindrome Metabolico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65441305P | 2005-02-18 | 2005-02-18 | |
| PCT/IB2006/001758 WO2006117696A2 (en) | 2005-02-18 | 2006-02-17 | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007009985A true MX2007009985A (es) | 2008-03-11 |
Family
ID=37086084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007009985A MX2007009985A (es) | 2005-02-18 | 2006-02-17 | Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1853552A2 (es) |
| JP (1) | JP2008530198A (es) |
| CN (1) | CN101128418A (es) |
| AU (1) | AU2006242851A1 (es) |
| BR (1) | BRPI0607140A2 (es) |
| CA (1) | CA2598491A1 (es) |
| MX (1) | MX2007009985A (es) |
| WO (1) | WO2006117696A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006256442A1 (en) * | 2005-03-22 | 2006-12-14 | Bellus Health (Innodia) Inc. | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| WO2008154743A1 (en) * | 2007-06-19 | 2008-12-24 | Innodia Inc. | Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof |
| US20110136911A1 (en) * | 2007-12-20 | 2011-06-09 | The Feinstein Institute For Medical Research | Treatment of sepsis and inhibition of mif by d-t4 |
| US10100066B2 (en) | 2015-10-23 | 2018-10-16 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-GATOR2 interaction and uses thereof |
| AU2018258355B2 (en) | 2017-04-26 | 2024-05-30 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| AU2019364542B2 (en) | 2018-10-24 | 2025-08-28 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| WO2021087432A1 (en) | 2019-11-01 | 2021-05-06 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mtorc1 modulator |
| CN112089710B (zh) * | 2020-08-07 | 2022-04-01 | 郑州大学 | 4-羟基异亮氨酸在制备抗肿瘤药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797767B1 (fr) * | 1999-08-27 | 2002-06-14 | Centre Nat Rech Scient | Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances |
| JP2008500955A (ja) * | 2003-10-27 | 2008-01-17 | イノディア インコーポレイテッド | 糖尿病の治療に使用するための方法及び組成物 |
| EP1657236A1 (en) * | 2004-11-10 | 2006-05-17 | Centre National De La Recherche Scientifique (Cnrs) | Method for preparing diastereoisomers of 4-hydroxy isoleucine |
-
2006
- 2006-02-17 WO PCT/IB2006/001758 patent/WO2006117696A2/en not_active Ceased
- 2006-02-17 BR BRPI0607140-6A patent/BRPI0607140A2/pt not_active Application Discontinuation
- 2006-02-17 AU AU2006242851A patent/AU2006242851A1/en not_active Abandoned
- 2006-02-17 CA CA002598491A patent/CA2598491A1/en not_active Abandoned
- 2006-02-17 CN CNA2006800050682A patent/CN101128418A/zh active Pending
- 2006-02-17 MX MX2007009985A patent/MX2007009985A/es not_active Application Discontinuation
- 2006-02-17 EP EP06765601A patent/EP1853552A2/en not_active Withdrawn
- 2006-02-17 JP JP2007555732A patent/JP2008530198A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006117696A3 (en) | 2007-01-25 |
| AU2006242851A1 (en) | 2006-11-09 |
| CA2598491A1 (en) | 2006-11-09 |
| JP2008530198A (ja) | 2008-08-07 |
| CN101128418A (zh) | 2008-02-20 |
| EP1853552A2 (en) | 2007-11-14 |
| WO2006117696A2 (en) | 2006-11-09 |
| BRPI0607140A2 (pt) | 2009-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008042688A3 (en) | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 | |
| WO2007061661A3 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2009091576A3 (en) | Parenteral formulations of dopamine agonists | |
| UA102429C2 (ru) | Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение | |
| WO2006002909A3 (en) | Sphingolipids against pathological processes in lipid rafts | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| WO2008134828A8 (en) | Tissue degeneration protection | |
| UA100384C2 (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
| TW200738246A (en) | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | |
| WO2008055940A3 (en) | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions | |
| CA2478237A1 (en) | Use of adapalene for the treatment of dermatological disorders | |
| EP2982696A3 (en) | Treatment of acute lymphoblastic leukemia | |
| WO2007064931A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2007059372A3 (en) | Use of chloroquine to treat metabolic syndrome | |
| WO2008124505A3 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
| WO2006099941A8 (de) | Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| MY148844A (en) | Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | |
| WO2006120574A3 (en) | Analogs of 4-hydroxyisoleucine and uses thereof | |
| PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
| WO2007107008A8 (en) | Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity | |
| WO2007010281A3 (en) | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | |
| MX2007009985A (es) | Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos. | |
| WO2007016679A3 (en) | Combination immediate release controlled release levodopa and carbidopa dosage forms | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2006131836A3 (en) | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |